SCHEMBL458514

SCHEMBL458514

C=CCN(CC=C)c1cccc(C(=O)O)c1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.41
PTPN1 P18031 1/20 0.39
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 3/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
POLB P06746 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
C5AR1 P21730 1/20 0.36
TDP1 Q9NUW8 2/20 0.36
PTGER1 P34995 1/20 0.36
MYC P01106 2/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
AKR1B10 O60218 1/20 0.36
TRPA1 O75762 1/20 0.36
ABCB11 O95342 1/20 0.36
DHFR P00374 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28431721 0.85 NR3C1 (0.40) TSHRPTPN1ALDH1A1HPGDPOLB
SCHEMBL278676 0.83 PTPN1 (0.47) TSHRPTPN1ALDH1A1KDM4EHPGD
SCHEMBL11333394 0.83 PTPN1 (0.37) TSHRPTPN1ALDH1A1KDM4ESMN1; SMN2
Hydrochloric Acid SCHEMBL27897977 0.82 PTPN1 (0.46) TSHRPTPN1ALDH1A1KDM4EHPGD
SCHEMBL11587536 0.82 PTPN1 (0.38) TSHRPTPN1ALDH1A1KDM4EHPGD
SCHEMBL6527883 0.81 G6PD (0.50) TSHRPTPN1ALDH1A1KDM4EHSD17B10
SCHEMBL11522678 0.80 TP53 (0.45) TSHRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL11639327 0.79 ALOX5 (0.52) TSHRPTPN1ALDH1A1KDM4EHPGD
SCHEMBL10346380 0.78 ALDH1A1 (0.41) TSHRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL11767364 0.78 AKR1C3 (0.44) TSHRPTPN1ALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1906945-B1 HCV INHIBITORS VIROBAY INC (US) 2015-08-05 EP disclosed
US-20150191459-A1 CATHEPSIN INHIBITORS VIROBAY, INC. 2015-07-09 US disclosed
EP-2078009-B1 NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 SANOFI SA (FR) 2015-03-18 EP disclosed
EP-1663958-B1 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY INC (US) 2015-02-25 EP disclosed
EP-2079683-B1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY INC (US) 2015-01-21 EP disclosed
US-20140256698-A1 CATHEPSIN INHIBITORS VIROBAY, INC. 2014-09-11 US disclosed
US-20140221478-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2014-08-07 US disclosed
EP-2361243-B9 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY INC (US) 2014-06-11 EP disclosed
US-8748649-B2 Di-fluoro containing compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2014-06-10 US disclosed
US-20140142110-A1 KINASE INHIBITOR SANOFI (FR) 2014-05-22 US disclosed
WO-1999054321-A1 SUBSTITUTED DIAMINES AND THEIR USE AS CELL ADHESION INHIBITORS AVENTIS PHARMA LIMITED (GB) 1999-10-28 WO disclosed
EP-0934307-A1 SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE RHONE-POULENC RORER LIMITED (GB) 1999-08-11 EP disclosed
WO-1999033789-A1 SUBSTITUTED β-ALANINES AVENTIS PHARMA LIMITED (GB) 1999-07-08 WO disclosed
WO-1999023063-A1 SUBSTITUTED ANILIDES AVENTIS PHARMA LIMITED (GB) 1999-05-14 WO disclosed
WO-1998056788-A1 IMIDAZOLYL-CYCLIC ACETALS RHONE-POULENC RORER LIMITED (GB) 1998-12-17 WO disclosed
WO-1998032734-A1 SUBSTITUTED β-THIOCARBOXYLIC ACIDS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-07-30 WO disclosed
WO-1998005327-A1 SUBSTITUTED AROMATIC COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-02-12 WO disclosed
WO-1997048697-A1 SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE RHONE-POULENC RORER LIMITED (GB) 1997-12-24 WO disclosed
WO-1997003967-A1 SUBSTITUTED AROMATIC COMPOUNDS AND THEIR PHARMACEUTICAL USE RHONE-POULENC RORER LIMITED (GB) 1997-02-06 WO disclosed
WO-1996031476-A1 AROMATIC HYDROXYETHERS RHONE-POULENC RORER LIMITED (GB) 1996-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191459-A1 CATHEPSIN INHIBITORS CTSF, CTSZ, CTSV TSHR 4088/4885PTPN1 3860/4885ALDH1A1 3635/4885
US-20140221478-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS CTSF, CTSZ, CTSS TSHR 4739/4885PTPN1 3521/4885ALDH1A1 1867/4885
US-20140256698-A1 CATHEPSIN INHIBITORS CTSF, CTSZ, CTSV TSHR 4088/4885PTPN1 3860/4885ALDH1A1 3635/4885
US-20140142110-A1 KINASE INHIBITOR MAP3K1, MAP3K20, MAP3K19 TSHR 3548/4885PTPN1 566/4885ALDH1A1 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.